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guanfacine extended release (GXR), to long-acting psychostimulants vs. maintain-
ing existing long-acting psychostimulant monotherapy in children and adoles-
cents with ADHD and suboptimal response to psychostimulant monotherapy.
METHODS: A one-year Markov model was developed from a US third-party payer
perspective. Effectiveness was measured by quality-adjusted life year (QALY). The
model assumed patients transitioned among four health states (normal, mild,
moderate, and severe), defined based on the Clinical Global Impressions-Severity
(CGI-S) scale. Transition probabilities were estimated in an ordered logit model
using patient-level data from a Phase III clinical trial comparing psychostimulants
plus GXR with psychostimulants plus placebo (n461). The model assumed that
patients in moderate or severe states after week eight would discontinue ADHD
treatment and remain in that state. Direct costs included drug wholesale acquisi-
tion costs (WAC) and medical costs, in 2010 US dollars. Health state utilities were
obtained from the literature. Disutilities associated with adverse events were ap-
plied for the first four weeks. One-way sensitivity analyses (SA) were conducted by
varying key model inputs. RESULTS: Adding GXR to existing psychostimulant
monotherapy was associated with an incremental drug cost of $1016 but lower
medical cost of $124, resulting in a total one-year incremental cost of $892. The
addition of GXR led to an incremental QALY of 0.03 and an incremental cost-
effectiveness ratio (ICER) of $31,660/QALY. In one-way SA, ICERs ranged from
$19,723/QALY to $46,631/QALY. CONCLUSIONS: This is the first cost-effectiveness
analysis of psychostimulants with adjunctive medication. Adjunctive therapy of
GXR with psychostimulants is cost-effective based on a willingness-to-pay thresh-
old of $50,000/QALY.
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OBJECTIVES: To determine the cost-effectiveness of TRT with TU (NEBIDO®) com-
pared with placebo for patients with ADAM and DM2, from the Brazilian Private
Healthcare System perspective. METHODS: The study was a cost-effectiveness
analysis based on Markov modeling to estimate costs and consequences of treat-
ments. Epidemiological and efficacy data derived from a critical appraisal of the
scientific literature. Only direct medical costs were considered. If available, costs of
clinical events (CE) were obtained from burden of disease studies. If not, Brazilian
official guidelines were obtained to determine the resources used to treat the CE.
Drug, hospital daily admission rates, procedures and laboratory tests unit costs
were obtained from Brazilian official databases. Costs and benefits were dis-
counted at 5% yearly. Outcomes were expressed as CE avoided. Probability sensi-
tivity analysis (PSA) was conducted to assess model robustness. Life time horizon
was analyzed. RESULTS: The systematic review showed that although the absence
of studies directly evaluating the impact of TU on cardiovascular events, their
favorable influence on cardiovascular disease intermediate markers suggests that
TU may have clinically relevant effect in patients at risk, especially in patients with
metabolic syndrome and/or DM2. The analysis showed higher clinical benefits and
costs for TU. Considering 100 patients, 75.2 and 140.0 CE happen in TU and placebo
arms, respectively. The average time-horizon cost per patient was
R$34,120(€14,896) and R$23,489(€10,255) for TU and placebo, respectively, resulting
in an incremental cost-effectiveness ratio (ICER) of R$16,390/CE avoided (€7,155/CE
avoided). PSA demonstrated that in 83.2% of the simulations TU was more effective
with higher cost and in 16.8% of the simulations TU was dominant compared to
placebo. CONCLUSIONS: Our study demonstrated that TU have clinically relevant
effect in reducing CE being highly cost-effective for ADAM treatment in patients
with DM2 at willingness-to-pay beyond R$19,000/CE avoided (€8,296/CE avoided)
(Brazilian GDP per capita). PSA confirmed this determinist result.
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OBJECTIVES: To estimate values for cost and effectiveness that assess the long-
term efficiency of public health intervention to prevent and correct childhood
obesity. METHODS: A Markov model was developed that takes into account five
diseases strongly associated with obesity: Diabetes Mellitus Type 2, Heart Disease,
Breast Cancer, Colon Cancer and Stroke. Selection of disease was in base of high
rates of morbidity and mortality. In the model, we considered 2 main states: nor-
mal weight (BMI 30 kg/m2) and obese (BMI 30 kg/m2). From them, individuals
can transit to states which representing the 5 diseases and death. Individuals can
transit between normal weight and obese until they reach a certain age (30) when
they can transit to the rest of states. The time horizon was 70 years. A literature
review was performed in order to estimate parameters. The measure of effective-
ness was QALYs and a discount of 3% was applied to costs and utilities. A 2-way
probabilistic sensitivity analysis was made over 2 parameters which define the
intervention: relative risk and cost of intervention. Also, a multivariate and prob-
abilistic sensitivity analysis by 2nd order Monte Carlo (MC) simulations was per-
formed for all parameters. Finally, acceptability curves and the expected value of
perfect information were calculated. RESULTS: If the willingness to pay is € 30,000/
QALY, any intervention that exceeds 1% prevention/correction, incurring in cost
not exceeding € 2 per child and per year should be implemented, because the
probability of hitting the decision is over 90% and does not incur on any opportu-
nity cost. CONCLUSIONS: Long term efficient public health interventions, to pre-
vent/correct childhood obesity, are low cost (not exceeding € 5 per child per year)
due to the effectiveness of interventions, usually lower than 2% of prevention/
correction over non-intervention.
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OBJECTIVES: Dienogest (Visanne ®) is a progestin that has recently been approved
in Europe, Australia and Japan (not in Korea yet) for the treatment of endometriosis
at a dose of 2 mg orally per day. Dienogest provides potent progestogenic effects,
combined with moderate suppression of estrogen levels and has no significant
androgenic, mineralocorticoid, or glucocorticoid activity. The aim of this analysis is
to evaluate cost-effectiveness of dienogest, thereby assessing its eligibility for Na-
tional Health Insurance coverage. METHODS: We carried out a cost-effectiveness
analysis comparing dienogest to leuprolide acetate, a gonodotropin releasing hor-
mone agonist (GnRH-agonist), the current standard treatment for endometriosis
associated pain after laparoscopy. Patients requiring additional treatment because
of pain after laparoscopy were included in the analysis. A third-party-payer per-
spective was taken. The time horizon of analysis was one year. Response to treat-
ment, time horizon of analysis, recurrence rate following discontinuation of
GnRH-a and the incidence of adverse event were considered as major factors for
the decision tree model. An expert survey was conducted to investigate the treat-
ment pattern. Costs of endometriosis were also assessed. In the base case scenario
patients do not receive any sequential treatment after non response or pain recur-
rence. Sensitivity analysis was performed for major variables. RESULTS: At the
base case analysis, dienogest was dominant. Sensitivity analysis showed that the
result was robust for the most variables. Drug cost was the most influential factor
of all. CONCLUSIONS: Dienogest is a cost-effective and cost-saving alternative in
the Korea National Health Insurance context. However the analysis is covering only
one year and long-term clinical data is required to draw a solid conclusion.
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OBJECTIVES: To evaluate the projected health outcomes, costs, and cost-effective-
ness of universal mass vaccination (UMV) with Rotarix™ (GlaxoSmithKline) in Can-
ada compared with no vaccination. METHODS: An age-compartmental, determin-
istic, static Markov cohort model was developed to simulate the disease process of
acute diarrhea events caused by rotavirus infection up to the age of 5 years in
‘monthly’ time cycles, using Canadian demographic and epidemiology data. The
base-case analysis was performed to estimate the direct effects of a UMV program
with two doses of Rotarix™ at 2 and 4 months of age compared to no vaccination,
assuming 90% vaccination coverage. Costs and utilities were discounted at 3.5%.
The efficacy of Rotarix™ was based on published clinical trial results. Model out-
puts include clinical endpoints (deaths, hospitalizations, emergency department
(ED) visits and outpatient visits), and economic measures (net costs per case/death
prevented and quality-adjusted life year gained). Incremental cost-effectiveness
ratios (ICERs) were calculated from the healthcare system perspective, and produc-
tivity loss was reported separately. One-way sensitivity analysis was performed to
evaluate the robustness of the model to variations in the underlying input
parameters. RESULTS:Without vaccination, a Canadian birth cohort of 380,000 can
be expected to have 152,000 rotavirus diarrhea events, 9,000 hospitalizations,
20,849 ED visits, 2,812 nosocomial infections and 6 deaths over 5 years. The base
case results show that a UMV program with Rotarix™ could reduce these events by
69%, 81%, 68%, 76% and 79% respectively over 5 years. At $60 per dose plus $9
administrative fee, the cost per QALY gained over no vaccination is $28,653.
CONCLUSIONS:A UMV program with Rotarix™ is projected to substantially reduce
the health and economic burden of rotavirus infections, and is cost-effective rela-
tive to no vaccination in the Canadian health care system.
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OBJECTIVES: Evaluate the potential benefits of the 10-valent pneumococcal non-
typeable Haemophilus influenzae (NTHi) protein D-conjugated vaccine (PHiD-CV)
and the 13-valent conjugated pneumococcal vaccine (PCV-13) for Argentina.
METHODS: A cohort Markov model was used. The model simulated the impact of
pneumococcal and NTHi related diseases (Invasive Disease (ID), Community Ac-
quired Pneumonia (CAP), and Acute Otitis Media (AOM)) in an argentinean cohort
followed over lifetime. Argentine epidemiology, disease management, and costs
were included in the model. Base case includes conservative assumptions on the
rates of NTHi infections. A 21 vaccination schedule was assumed, with vaccine
coverage of 90% and 2 prices/dose scenarios a) PAHO Revolving Fund 2011 prices, or
b) price parity. Results of the quality adjusted life years gained (QALYs) and future
averted costs, using a 3.5% discount rate, using the health payer perspective, are
presented. RESULTS: The model estimated comparable results between vaccines
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on mortality associated to ID and CAP, for the base case scenario. It predicts that
vaccines would reduce 11.34 deaths (PCV-13) and 11.03 deaths (PHiD-CV) per
100,000 vaccinated infants. Besides, PHiD-CV would reduce 221 more myringoto-
mies and 3,891 more AOM cases than PCV-13, per 100,000 vaccinated infants. The
direct medical costs averted (undiscounted) due to ID and CAP is similar for both
vaccines. Instead, PHiD-CV would save 1.9 times more AOM medical costs than
PCV-13. Both vaccines are cost effective, but PHiD-CV would generate more QALY
gains (1176 additional QALYs) and in addition, would be cost saving. It was esti-
mated that PHiD-CV requires a reduced annual investment of 10 million (PAHO
prices) or 1.6 million (price parity) US$, compared to PCV-13. CONCLUSIONS: Both
vaccines would reduce significantly the impact of invasive pneumococcal disease
and CAP, but PHiD-CV will generate more QALYs gain and will be cost saving
compared to PCV-13, due to its greater effects over AOM.
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OBJECTIVES: Despite recent progress in our understanding of the economics of
ADHD in children and adolescents, little is known about the comparative cost
effectiveness of treatment strategies for adult ADHD. Even for ADHD in children,
there is a shortage of robust data supporting the cost effectiveness of psychother-
apeutic interventions.METHODS: A randomized, double-blind, placebo-controlled
multicenter study has been initiated in Germany, enrolling 448 adult patients with
ADHD. Patients are assigned to one out of four parallel treatment arms: 1) a struc-
tured disorder tailored psychotherapy (dialectical behavioral therapy, DBT) plus
medication (methylphenidate); 2) DBT and placebo; 3) psychiatric counseling with-
out specific behavioral interventions (clinical management) plus medication; or 4)
clinical management and placebo. DBT and clinical management are administered
weekly for the first 12 weeks and on a four-weekly basis thereafter, until the end of
the one-year-observation period. An additional follow-up investigation is sched-
uled at 18 months after treatment termination. RESULTS: Endpoints include symp-
tomatic improvement (primary endpoint: Conners’ Adult Rating Scale, blind-ob-
server rated), general psychopathology, clinical global impression, and a disorder-
specific quality of life questionnaire. In order to facilitate cost utility analysis,
health-related quality of life is also measured by means of the EQ-5D and SF-36. For
primary analysis, the perspective of Statutory Health Insurance will be adopted;
resource use and costing from a societal perspective will be done for secondary
analyses. Probabilistic sensitivity analyses will be done using nonparametric boot-
strapping on the basis of patient-level study data. CONCLUSIONS: The COMPAS
Study will, for the first time, provide insights into the cost effectiveness of a disor-
der tailored psychotherapy for adult ADHD. Key hypotheses are: 1) that combined
treatment (study arm 1) is more effective than either option (DBT or medication)
alone, both short and long term, and 2) that a tailored psychotherapeutic interven-
tion will meet broadly accepted benchmarks of cost effectiveness.
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OBJECTIVES:To estimate the cost effectiveness of dienogest versus GnRH analogue
(GnRH-a) for the treatment of endometriosis-associated chronic pelvic pain in Slo-
vakia for 5 years time horizon. METHODS: A cost-utility Markov model based on
results of randomized controlled trial (AU19) was adapted to a Slovakian setting.
The AU19 trial, which compared dienogest and GnRH-a (leuprolide) in the treat-
ment of endometriosis-associated chronic pelvic pain over a 6 month period,
showed no statistically significant differences in response rates. The dienogest
annual relapse rate was derived from 52-weeks extension study, while relapse
rates for the GnRH-a were derived from the literature. Local cost data was based on
published price lists, clinical guidelines, product labels and expert opinion. QoL
related utilities were derived from individual patient SF-36 scores from AU19 da-
taset. Effectiveness was measured in quality-adjusted life years (QALY). Time ho-
rizon was set at five years and a payers’ perspective was adopted. Discount rate was
5% per year for both costs and effects according to valid Ministry of Health (MoH)
guidelines for health economic evaluation. Both one-way and probabilistic sensi-
tivity analyses were performed. RESULTS: Dienogest showed that it was cost-ef-
fective compared to a GnRH-a, with an overall cost reduction of 426 € and a QALY
gain of 0.069 per patient. Cost reduction was due to both the differences in the
average drug cost during the two year period and the average laparoscopy cost. In
probabilistic sensitivity analysis 92 % of simulations were below 18,000 €/QALY,
which is the officially published threshold for willingness to pay in Slovakia. In 79%
of cases dienogest treatment was dominant over GnRH-a. CONCLUSIONS: Dieno-
gest is a cost-effective alternative to GnRH analogue for the treatment of endo-
metriosis-associated chronic pelvic pain in a Slovakian setting in a five-year time
horizon.
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OBJECTIVES: The majority of individuals with chronic hepatitis C virus (HCV) are
adults, and there is much experience in Australia with interferon-based treat-
ments in adults using combination pegylated- interferon and ribavirin treatment.
Pegylated-interferon alfa-2b was first approved for adult use in Australia and for
reimbursement in 2003. It is currently reimbursed for initial treatment, and for a
single retreatment course. Nonetheless, a limited number of children and adoles-
cents in Australia contract the disease. Currently these individuals have no regis-
tered or reimbursed approved therapies available to them. This analysis reports a
cost-effectiveness analysis of a single course of initial pegylated-interferon alfa-2b
therapy in paediatrics with a bodyweight of at least 27 kg, reflecting the lowest
dosage that will be supplied in Australia. METHODS: A cost-utility analysis was
conducted using a lifetime Markov model. Analysis of paediatric treatment versus
no treatment was undertaken to determine the impact expansion of reimburse-
ment would have on the cost-effectiveness of the total population. Data were
sourced from a study assessing sustained virological response, and the literature
reporting the natural history and utility weights regarding HCV. RESULTS: Down-
stream cost-offsets associated with treatment reduce the total incremental cost
from AU$13,208 to AU$4767. These cost-offsets arose from avoidance of down-
stream transitions to more severe and costly states of health. Treatment was also
shown to be associated with improvements in health-related quality of life due to
the downstream avoidance of more serious health states as well as the obvious
improvement in viral clearance. Over the lifetime of a patient, the base case anal-
ysis estimated an improvement of approximately 2.01 QALYs, generating an incre-
mental cost-effectiveness ratio of AU$2373 per QALY. CONCLUSIONS: Expanding
reimbursement to include paediatric treatment of chronic HCV is a highly cost-
effective way to equitably treat chronic HCV, regardless of age.
Individual’s Health – Patient-Reported Outcomes & Preference-Based Studies
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BACKGROUND: Conducting pediatric studies is complex and the most significant
barrier is infant enrollment by parental consent. This obstacle is currently found
both for healthy and sick infants. The reason for the parents’ refusal to consent is
not obvious and may be due to multiple factors. OBJECTIVES: To identify the fac-
tors influencing parents’ decisions to refuse infant participation in pediatric
studies. METHODS: Observational, transversal study carried out by French phar-
macists randomly selected among the 2,090 pharmacies of the In fine PHARMA®
network (representative of French pharmacies in terms of geographic location and
sales). Parents presenting to participating pharmacies were eligible. Data were
collected through questionnaires fulfilled by participating parents. RESULTS:
Twenty-one pharmacists agreed to participate and enrolled 105 participating par-
ents. Among them, 78 (74%) filled out a questionnaire. Participating families had an
average of 2.3 children, 81% were living in an urban environment, and 51% of the
infants were males. Most of the parents (97%) had never enrolled their children in
a study. Main deterrents to parental consent were: they viewed pediatric studies as
risky (35%), they did not want their infant to be treated as an experimental animal
(20%), their infant was not ill (12%), the information provided by the physician was
too confusing and/or complicated (10%). Parents may have been willing to have
their child participate in a study only if the study was evaluating a new drug, their
child’s participation would further medical research (31%), their child suffered
from a severe illness (24%), and they had great confidence in their physician (22%).
CONCLUSIONS: The results of this survey show that the factors negatively influ-
encing parents’ decisions to consent were the perceived risk presented by the
studies, the lack of interest to medical research if their child was not ill, and the lack
of information about the study.
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OBJECTIVES:Medication nonadherence among patients with chronic conditions is
a significant barrier to achieving therapeutic outcomes. The objective of this study
was to identify patient reported factors and reasons associated with medication
nonadherence. METHODS: Online cross-sectional survey of patients taking medi-
cations for seven chronic conditions: asthma/COPD, bipolar depression, cardiovas-
cular disease, diabetes, neuropathic pain, osteoporosis, and rheumatoid arthritis.
The first 50 patients to respond to the survey for each of the seven conditions were
evaluated (total n350). Patients provided demographic information and answered
questions about their drug therapy including knowledge and satisfaction with their
medications, difficulties in taking their medications, and how often they take their
medication as prescribed. Adherence was defined as patients self-reporting that
they always take their medication as prescribed. Nonadherence was defined as
never, sometimes or often take medications as prescribed. Multivariate logistic
regression was performed to identify patient factors and reasons associated with
nonadherence. RESULTS: Among the 350 patients who completed the survey, the
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